A review of the inhibitory waste metabolites produced during mAb biomanufacturing

Chinese hamster ovary (CHO) cell culture underpins commercial manufacturing of most therapeutic monoclonal antibodies, yet productivity and product quality remain constrained by inhibitory metabolic by-products that accumulate across batch, fed-batch, and perfusion processes. While lactate and ammonium have historically dominated monitoring and control strategies, untargeted metabolomics and stable-isotope tracing have substantially expanded the inventory of bioprocess-relevant inhibitors. This review synthesizes current understanding of 17 inhibitory metabolites spanning eight metabolic pathways. These include branched-chain amino acid catabolites (isobutyrate, isovalerate, and 2-hydroxyisocaproate), aromatic amino acid derivatives (phenyllactate, indole-3-carboxylate), nucleotide-pathway by-products (cytidine monophosphate, guanosine monophosphate, and succinyladenosine), and apoptosis-correlated species such as glycerol-3-phosphocholine and oxidized glutathione. Reported concentration thresholds are compiled for better-studied inhibitors, while correlative evidence linking accumulation to apoptosis, reduced productivity, and altered glycosylation is summarized. We evaluate the analytical workflow combining LC-MS and NMR for discovery, Raman spectroscopy for in-line monitoring, and stable-isotope tracing for pathway validation. Control strategies are critically compared across three tiers: media and feed reformulation (amino acid limitation, dynamic pH, or oxygen-uptake-rate-driven feeding), targeted and multiplex genetic engineering (BCAT1 knockout, combined LDHA/PDK editing), and keto-acid precursor substitution. We close by identifying concrete gaps, chiefly the absence of cell-line-independent inhibition thresholds, and argue that coupling genome-scale metabolic models with PAT data is the logical next step toward predictive, closed-loop mAb manufacturing.